SignatureFD’s Adicet Bio ACET Stock Holding History

SignatureFD’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$22	–	3125
2023 Q3	$22	Hold	1	–	–	﹤0.01%	3167
2023 Q2	$39	Sell	1 -3	-75%	-$265	﹤0.01%	3197
2023 Q1	$397	Buy	+4	New	+$502	﹤0.01%	3127
2022 Q4	–	Sell	-7	Closed	-$2K	–	3281
2022 Q3	$2K	Buy	7 +4	+133%	+$1.01K	﹤0.01%	2722
2022 Q2	$1K	Buy	+3	New	+$659	﹤0.01%	2861

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SignatureFD's ACET Position: Q4 2023 in Review

SignatureFD sold out of Adicet Bio (ACET) in Q4 2023, closing a stake of 1 share — an estimated $22 sold.

SignatureFD first reported a position in ACET in Q2 2022 and held it in 5 quarters. The position peaked at $2K in Q3 2022. 76 funds tracked by Wall St. Rank hold ACET as of Q4 2023.

SignatureFD reported no remaining Adicet Bio position as of Q4 2023 after selling out during the quarter.
SignatureFD sold 1 Adicet Bio share in Q4 2023, an estimated $22.
SignatureFD first reported a position in Adicet Bio in Q2 2022 and held it in 5 quarters.
SignatureFD's Adicet Bio position peaked at $2K in Q3 2022.
76 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.